SAB Biotherapeutics, Inc. financial data

Symbol
SABS, SABSW on Nasdaq
Location
Miami Beach, FL
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 09 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 574% % 31%
Debt-to-equity 21% % -50%
Return On Equity 15% %
Return On Assets 13% %
Operating Margin -1647% % -258%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50,951,037 shares 449%
Common Stock, Shares, Outstanding 47,609,899 shares 413%
Entity Public Float $76,734,681 USD 293%
Common Stock, Value, Issued $4,766 USD 410%
Weighted Average Number of Shares Outstanding, Basic 19,311,798 shares 109%
Weighted Average Number of Shares Outstanding, Diluted 61,340,193 shares 562%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $2,780,084 USD -57%
Research and Development Expense $34,352,332 USD 14%
General and Administrative Expense $14,601,031 USD 4.4%
Operating Income (Loss) $48,953,363 USD -14%
Nonoperating Income (Expense) $62,227,046 USD 607%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $45,567,373 USD -68%
Net Income (Loss) Attributable to Parent $13,273,683 USD -48%
Earnings Per Share, Basic 0.22 USD/shares
Earnings Per Share, Diluted -0.79 USD/shares 79%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $10,502,680 USD 18%
Assets, Current $101,052,624 USD 325%
Property, Plant and Equipment, Net $13,305,902 USD -13%
Operating Lease, Right-of-Use Asset $2,603,059 USD 168%
Assets $172,809,969 USD 291%
Accounts Payable, Current $3,145,805 USD 86%
Employee-related Liabilities, Current $5,036,039 USD 21%
Liabilities, Current $10,681,170 USD 34%
Operating Lease, Liability, Noncurrent $1,877,360 USD 223%
Liabilities $21,315,594 USD 17%
Accumulated Other Comprehensive Income (Loss), Net of Tax $186,510 USD
Retained Earnings (Accumulated Deficit) $110,895,167 USD 11%
Stockholders' Equity Attributable to Parent $151,494,375 USD 483%
Liabilities and Equity $172,809,969 USD 291%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,797,217 USD 27%
Net Cash Provided by (Used in) Financing Activities $173,985 USD 56%
Net Cash Provided by (Used in) Investing Activities $4,671,103 USD
Common Stock, Shares Authorized 800,000,000 shares 0%
Common Stock, Shares, Issued 47,664,564 shares 410%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $3,257,599 USD 92%
Interest Paid, Excluding Capitalized Interest, Operating Activities $70,011 USD 5.8%
Deferred Tax Assets, Valuation Allowance $36,870,709 USD 32%
Deferred Tax Assets, Gross $38,580,064 USD 30%
Operating Lease, Liability $2,674,762 USD 174%
Payments to Acquire Property, Plant, and Equipment $129,074 USD 506%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $13,595,603 USD -45%
Lessee, Operating Lease, Liability, to be Paid $3,157,309 USD 192%
Property, Plant and Equipment, Gross $30,822,364 USD 2.9%
Operating Lease, Liability, Current $797,402 USD 103%
Lessee, Operating Lease, Liability, to be Paid, Year Two $712,653 USD 81%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,007,017 USD 123%
Operating Lease, Weighted Average Discount Rate, Percent 0.0945 pure 22%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $482,547 USD 357%
Lessee, Operating Lease, Liability, to be Paid, Year Three $728,650 USD 740%
Deferred Tax Assets, Operating Loss Carryforwards $19,125,228 USD 30%
Preferred Stock, Shares Issued 42,019 shares -0.51%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $708,989 USD 686%
Operating Lease, Payments $1,000,000 USD 25%
Additional Paid in Capital $267,719,445 USD 72%
Preferred Stock, Shares Outstanding 42,019 shares -0.51%
Depreciation, Depletion and Amortization $2,994,763 USD -36%
Deferred Tax Assets, Net of Valuation Allowance $1,709,355 USD -8.5%
Share-based Payment Arrangement, Expense $5,210,647 USD 77%
Interest Expense $317,069 USD -2.7%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%